AI-generated summary
The authors prospectively studied 366 patients with chalazion treated with intralesional triamcinolone, intense pulsed light, or both, and built a hybrid AI-clinical model to predict recurrence. They report that combined treatment had higher 3-month resolution and lower recurrence than either treatment alone, and that the hybrid model predicted recurrence better than the clinical model alone. The abstract describes these as observational findings.
- Participants
- 366
- Who or what was studied
- Patients with chalazion (366 enrolled in a prospective observational study)
- Limits stated in the abstract
- The study is observational and non-randomized, so treatment group comparisons may be confounded, and the abstract does not describe external validation of the model.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Purpose
To evaluate the rates of chalazion recurrence following intralesional triamcinolone acetonide (TA), intense pulsed light (IPL), or combined TA + IPL therapy and to validate an AI-enhanced risk stratification strategy.
Methods
This prospective, observational study enrolled 366 patients. To eliminate immortal time bias and circular reasoning, LASSO-Cox regression with 10-fold cross-validation was employed to identify purely baseline predictors: age, Demodex infection, chronicity, and meibomian gland dysfunction (MGD). These baseline predictors were integrated into a clinical Cox proportional hazards model and a survival-based XGBoost model, which were subsequently merged into a hybrid framework. Performance was assessed via time-dependent area under the curve (AUC), net reclassification improvement (NRI), Kaplan-Meier analysis, and decision curve analysis (DCA).
Results
The 3-month complete resolution rate was significantly higher in the combined TA + IPL group (95.2%) compared to the TA-only (90.8%) and IPL-only (79.4%) groups (p < 0.001). During follow-up, 60 recurrence events (16.4%) occurred. Recurrence rates differed significantly (χ2 = 31.73, p < 0.001) as follows: IPL group (38.2%), TA group (15.4%), and TA + IPL group (8.3%). Multivariate Cox analysis revealed that demodex infection, age, chronicity, and MGD were independent risk factors for chalazion recurrence. The hybrid model achieved an AUC of 0.822, outperforming the clinical (0.745) and XGBoost (0.821) (p < 0.05) models. AI integration significantly refined the risk estimates (NRI = 0.365, p = < 0.001). In the high-risk subgroup, recurrence rates reached 83.3-91.7% with monotherapy, whereas combined TA + IPL therapy significantly reduced the recurrence rate to 60.0%. DCA confirmed that the hybrid model consistently yielded the greatest net clinical benefit.
Conclusion
A hybrid AI-clinical model significantly improved the prediction of chalazion recurrence. Combined TA + IPL therapy demonstrated superior efficacy, particularly for high-risk patients. This framework provides a robust decision-support tool for precision management and the systematic reduction of chalazion recurrence.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Observational study. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.